Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05925127 · ClinicalTrials.gov registry record · Phase 2
Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines
A Phase 2 study, sponsored by Novavax.
- Completed
- Registry status
- Phase 2
- Development phase
- 994
- Enrollment target
NCT05925127: Completed Phase 2 study, sponsored by Novavax.
NCT05925127 is a Phase 2 study that has completed, run by Novavax. The registered enrollment target is 994 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (647% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05925127, a Phase 2 study, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 994 participants
- Enrollment target
Study Summary
This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle (SARS-CoV-2 rS) vaccines with Matrix-M™ adjuvant (NVX-CoV2373 \[prototype Wuhan vaccine with Matrix-M adjuvant\] or NVX-CoV2601 \[Omicron XBB.1.5 subvariant vaccine with Matrix-M adjuvant\]).
Primary Outcome
Neutralizing antibody To determine if the combination of antigen and adjuvant levels of NVX-CoV2601 GMTR against the Omicron subvariant XBB.1.5 superior(LB of the 95% CI for GMTR \> 1.0) to that elicited by NVX-CoV2373
Interventions
- BIOLOGICAL NVX-CoV2373 (5μg)
- BIOLOGICAL NVX-CoV2601 (5μg)
- BIOLOGICAL NVX-CoV2601(5μg)
- BIOLOGICAL NVX-CoV2601 (35μg)
- BIOLOGICAL NVX-CoV2601(35μg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 994 participants |
| Start Date | 2023-10-16 |
| Est. Completion | 2024-05-21 |
| Phase | Phase 2 |
What the finished NCT05925127 record still lists
NCT05925127 is an interventional study that assigns participants to a tested intervention. The registered 994 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (647% higher).
The record links to 0 conditions, and to 5 interventions - of which NVX-CoV2373 (5μg) is the first listed.
NCT05925127 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05925127 about?
NCT05925127 is a clinical study titled "Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines". This is a Phase 2/3, randomized, double-blind study to evaluate the safety and immunogenicity of different booster dose levels of the monovalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle (SARS-CoV-2 rS) vaccines with Matrix-M™ adjuvan...
What is the current status of trial NCT05925127?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 994 participants. The study started on 2023-10-16. Estimated completion is 2024-05-21.
What interventions are being tested in trial NCT05925127?
The interventions under investigation include: NVX-CoV2373 (5μg) (BIOLOGICAL), NVX-CoV2601 (5μg) (BIOLOGICAL), NVX-CoV2601(5μg) (BIOLOGICAL), NVX-CoV2601 (35μg) (BIOLOGICAL), NVX-CoV2601(35μg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05925127?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05925127's enrollment target sits among peer trials
994 26th of 2000 higher than 1,975 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05437575 · 994 participants · Phase 3
Prehospital Analgesia INtervention Trial (PAIN)
- NCT06671704 · 994 participants · NA
GC-PRO Intervention
- NCT07005024 · 996 participants · Phase 3
DOAC - Dosing Options in AntiCoagulation Prophylaxis
- NCT05987241 · 992 participants · Phase 2
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI